GLPwatch
Papers (10588)
Page 165 of 177, ranked by citation count.
- Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.
- Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events in Patients With Type 2 Diabetes Mellitus Who Take Metformin.
- Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.
- Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.
- Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care.
- Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.
- Comparative Efficacy and Safety of Tirzepatide Versus Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
- Use of liraglutide in type 1 diabetes: implications for management.
- Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes.
- Cardiorenal Safety Markers With Injectable Glucagon-Like Peptide-1 (GLP-1) Agonists in Type 2 Diabetes: A Network Meta-Analysis.
- Semaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes.
- Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis.
- A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).
- Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports.
- GLP-1 receptor agonists in pediatric obesity.
- Digital multicriteria evaluation of negotiated medicines using Chinese mini-HTA: application of structured methodologies in assessing once-weekly GLP-1 RAs for improved clinical decision-making.
- Incretin-Based Therapies and Heart Failure Outcomes: Benefit Beyond Weight Loss?
- Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.
- Unimolecular GLP-1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta-Cell Survival and Glycaemic Regulation.
- GLP-1 receptor agonists in ADPKD: from metabolic rationale to phenotype-enriched translational testing.
- Intense Uptake of 68 Ga-exendin-4 in a Patient With WHO Grade 3 Insulinoma and Extensive Intrahepatic Metastases.
- Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050.
- [Effects of exendin-4 on rat cardiomyocyte apoptosis early after severe scald injury].
- Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL.
- Varying Hypopnea Definitions and Treatment Eligibility in Obstructive Sleep Apnea.
- [SURMOUNT-OSA study : tirzepatide improves obstructive sleep apnoea in patients with obesity].
- Exendin-4 - A potential therapeutic for type 2 diabetes-linked cervical cancer?
- A Single-dose, Two-Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese Subjects.
- Mapping Global Research on Adverse Effects of GLP-1 Receptor Agonists (2006-2025): A Scopus-Based Bibliometric and Thematic Analysis.
- Brachial Plexopathy Following Rapid Weight Loss from Tirzepatide: A Case Report.
- Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review.
- Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study.
- Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or Obesity.
- [Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications].
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25.
- Knowledge, Attitudes and Practices on the Use of Antidiabetic Medications for Weight Loss: A Cross-Sectional Study in the Lebanese Population.
- A multi-organ atlas of microcirculatory signatures for systemic profiling of diabetic and therapeutic states.
- CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.
- Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial.
- Repairing effects of liraglutide on spinal cord injury in rats via PI3K/AKT/ENOS signaling pathway.
- Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF.
- Real-world glycemic control, exploratory cardiorenal indicators, and safety of polyethylene glycol loxenatide versus semaglutide in type 2 diabetes patients: a Chinese two-center retrospective cohort study.
- Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis.
- [Exendin-4 improves impaired endothelial dependent vasodilation in obese rat].
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).
- [GLP-1 agonists: an overview].
- SemaGBA: A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight.
- Drug-induced liver injury secondary to tirzepatide.
- The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.
- Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials.
- Gila Monster Lizard & Incretin-mimetics.
- Insulin degludec + liraglutide (Xultophy°) in type 2 diabetes.
- Effect of Injectable Dual and Single Agonist Glucagon-Like Peptide-1 Based Therapy on Inflammatory Bowel Disease Activity Among Patients with Obesity.
- Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report.
- Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.
- Real-world prescribing patterns and early weight and blood pressure outcomes of GLP-1-based therapies: a retrospective observational study in the United Arab Emirates.
- The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer's and Parkinson's Disease: A Literature Review of Clinical Trials.
- [Cardiovascular morbidity and mortality in patients with kidney disease].
- Patient With Tirzepatide-treated Type 2 Diabetes With Difficult Visualization During Esophagogastroduodenoscopy.